Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. Bedaquiline (Sirturo) - pulmonary multidrug-resistant tuberculosis (MDR-TB)

Bedaquiline (Sirturo) - pulmonary multidrug-resistant tuberculosis (MDR-TB) Final Appraisal Recommendation Advice No: 0820 – September 2020 Bedaquiline (Sirturo ® ) 100 mg tablets Limited submission by Janssen Cilag Ltd Additional note(s): • AWMSG considered bedaquiline (Sirturo ® ) as an ultra-orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease. • This advice incorporates and replaces the existing AWMSG recommendation on bedaquiline (...) (Sirturo ® ) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (Advice number 0815, originally published March 2015). In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3726), which includes the AWMSG Secretariat Assessment Report (ASAR

2020 All Wales Medicines Strategy Group

2. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Full Text available with Trip Pro

Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Every year, at least one million children become ill with tuberculosis and around 200,000 children die. Xpert MTB/RIF and Xpert Ultra are World Health Organization (WHO)-recommended rapid molecular tests that simultaneously detect tuberculosis and rifampicin resistance in adults and children with signs and symptoms of tuberculosis, at lower health system levels. To inform updated WHO (...) guidelines on molecular assays, we performed a systematic review on the diagnostic accuracy of these tests in children presumed to have active tuberculosis.Primary objectives • To determine the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for (a) pulmonary tuberculosis in children presumed to have tuberculosis; (b) tuberculous meningitis in children presumed to have tuberculosis; (c) lymph node tuberculosis in children presumed to have tuberculosis; and (d) rifampicin resistance in children

2020 Cochrane

3. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. (Abstract)

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and anti-tuberculosis medications modify this risk are unclear. Our objective was to evaluate how use of these treatments altered mortality risk in HIV-positive adults (...) with multidrug-resistant tuberculosis.We did an individual patient data meta-analysis of adults 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis treatment between 1993 and 2016. Data included ART use and anti-tuberculosis medications grouped according to WHO effectiveness categories. The primary analysis compared HIV-positive with HIV-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding those lost to follow up

2020 Lancet

4. Pretomanid - drug-resistant tuberculosis

Pretomanid - drug-resistant tuberculosis Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/169333/2020 EMEA/H/C/005167 Pretomanid FGK (pretomanid) An overview of Pretomanid FGK (...) and why it is authorised in the EU What is Pretomanid FGK and what is it used for? Pretomanid FGK is a medicine for treating adults with drug-resistant tuberculosis. It is used to treat tuberculosis that is: • extensively drug-resistant (resistant to at least 4 antibiotics used for treating tuberculosis, including the standard antibiotics isoniazid and rifampicin); • multi-drug resistant (resistant to isoniazid and rifampicin) and when antibiotics used for this form of tuberculosis do not work

2020 European Medicines Agency - EPARs

5. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. (Abstract)

Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking.We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D3 (...) or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events.A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less

2020 NEJM

6. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. (Abstract)

Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.We conducted a 48-week trial of empirical treatment for tuberculosis as compared (...) with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter. Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol

2020 NEJM

7. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. (Abstract)

Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid. However, daily medication costs are higher for a 4-month rifampin regimen than a 9-month isoniazid regimen.To compare health care use and associated costs of 4 months of rifampin and 9 (...) months of isoniazid.Health system cost comparison using all health care activities recorded during 2 randomized clinical trials. (ClinicalTrials.gov: NCT00931736 and NCT00170209).High-income countries (Australia, Canada, Saudi Arabia, and South Korea), middle-income countries (Brazil and Indonesia), and African countries (Benin, Ghana, and Guinea).Adults and children with clinical or epidemiologic factors associated with increased risk for developing tuberculosis that warranted treatment for latent

2020 Annals of Internal Medicine

8. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Full Text available with Trip Pro

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas (...) of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available.We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria

2020 Lancet

9. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Full Text available with Trip Pro

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated (...) the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients

2020 NEJM

10. Current and future treatments for tuberculosis. Full Text available with Trip Pro

Current and future treatments for tuberculosis. Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform the landscape for treatment of drug sensitive TB, drug resistant TB, and latent TB infection. Multiple trials are evaluating novel agents, repurposed agents, adjunctive host directed therapies, and novel treatment strategies that will increase the probability

2020 BMJ

11. Tuberculosis among First Nations, Inuit and Métis children and youth in Canada: Beyond medical management

Tuberculosis among First Nations, Inuit and Métis children and youth in Canada: Beyond medical management First Nations, Inuit and Métis people in Canada continue to be disproportionately affected by tuberculosis (TB), a disparity rooted primarily in factors such as poverty, crowded and inadequate housing, food insecurity, and inequitable health care access. Historical TB control practices in Canada have contributed to stigma and discrimination toward those with the disease, as well (...) , improve the quality and uptake of services for treatment and prevention in families and communities at risk. They can also advocate for sustainable, community-driven TB elimination strategies that incorporate First Nations, Inuit and Métis principles of wellness, healing and self-determination.   Key words: First Nations, Inuit, Métis, Indigenous, child health, tuberculosis, LTBI, social determinants

2020 Canadian Paediatric Society

12. Tuberculosis and pregnant women

Tuberculosis and pregnant women Tuberculosis and pregnant women - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis and pregnant women Guidance for patients and the public and for clinical staff involved in treating pregnant women. Published 1 November 2013 Last (...) . Please tell us what format you need. It will help us if you say what assistive technology you use. Details One set of guidance is for pregnant women and members of the public. The other is for clinical staff treating pregnant women who have had contact with a person with infectious tuberculosis ( 17 December 2019 Updated to reflect changes in national guidance and availability of services. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you

2020 Public Health England

13. Tuberculosis: information for prison and immigration removal centre staff

Tuberculosis: information for prison and immigration removal centre staff Tuberculosis: information for prison and immigration removal centre staff - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis: information for prison and immigration removal centre staff Advice (...) information for prison and immigration removal centre staff on: spotting symptoms of 17 December 2019 Updated 'Tuberculosis: information for prisons and immigration removal centre staff'. 22 March 2019 Updated guidance on 'Tuberculosis (TB): information for discipline and wing staff'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National

2020 Public Health England

14. Tuberculosis (TB) and homelessness

Tuberculosis (TB) and homelessness Tuberculosis (TB) and homelessness - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis (TB) and homelessness Advice for people who work in the homeless sector. Published 1 November 2013 Last updated 16 December 2019 — From: Documents (...) . It will help us if you say what assistive technology you use. Details People who work in the homelessness sector can use this information to help them to recognise 16 December 2019 Updated documents. 7 January 2016 Added 'Tuberculosis (TB) and homelessness: information for homelessness service managers'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like

2020 Public Health England

15. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Full Text available with Trip Pro

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Respir Crit Care Med Actions , 200 (10), e93-e142 2019 Nov 15 Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , PMID: 31729908 PMCID: DOI: Item in Clipboard Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA

2020 EvidenceUpdates

16. Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent Tuberculosis. Full Text available with Trip Pro

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity.From August 2014 through November 2015, we enrolled adults (...) 18 to 50 years of age with M. tuberculosis infection (defined by positive results on interferon-γ release assay) without evidence of active tuberculosis disease at centers in Kenya, South Africa, and Zambia. Participants were randomly assigned in a 1:1 ratio to receive two doses of either M72/AS01E or placebo, administered 1 month apart. The primary objective was to evaluate the efficacy of M72/AS01E to prevent active pulmonary tuberculosis disease according to the first case definition

2019 NEJM

17. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Full Text available with Trip Pro

Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Tuberculosis causes more deaths than any other infectious disease worldwide, with pulmonary tuberculosis being the most common form. Standard first-line treatment for drug-sensitive pulmonary tuberculosis for six months comprises isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) for two months, followed by HRE (in areas of high TB drug resistance) or HR, given over a four-month (...) ), in the Cochrane Library; MEDLINE (PubMed); Embase; the Latin American Caribbean Health Sciences Literature (LILACS); Science Citation Index-Expanded; Indian Medlars Center; and the South Asian Database of Controlled Clinical Trials. We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform, ClinicalTrials.gov, the Clinical Trials Unit of the International Union Against Tuberculosis and Lung Disease, the UK Medical Research Council Clinical Trials Unit

2019 Cochrane

18. Tuberculosis (TB) and children

Tuberculosis (TB) and children Tuberculosis (TB) and children - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis (TB) and children Guidance for all of those who work with children. Explains how (...) Updated 'Tuberculosis and children: information for all of those who work with children'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National Insurance number or credit card details. What were you doing? What went wrong? Send Help us improve GOV.UK To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you

2019 Public Health England

19. Transmissibility and potential for disease progression of drug resistant <i>Mycobacterium tuberculosis</i>: prospective cohort study. Full Text available with Trip Pro

Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. To measure the association between phenotypic drug resistance and the risk of tuberculosis infection and disease among household contacts of patients with pulmonary tuberculosis.106 district health centers in Lima, Peru between September 2009 and September 2012.Prospective cohort study.10 160 household contacts of 3339 index patients with tuberculosis were (...) classified on the basis of the drug resistance profile of the patient: 6189 were exposed to drug susceptible strains of Mycobacterium tuberculosis, 1659 to strains resistant to isoniazid or rifampicin, and 1541 to strains that were multidrug resistant (resistant to isoniazid and rifampicin).Tuberculosis infection (positive tuberculin skin test) and the incidence of active disease (diagnosed by positive sputum smear or chest radiograph) after 12 months of follow-up.Household contacts exposed to patients

2019 BMJ

20. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Full Text available with Trip Pro

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. The lateral flow urine lipoarabinomannan (LF-LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active tuberculosis in HIV-positive people with severe HIV disease. This review update asks the question, "does new evidence justify the use of LF-LAM in a broader group of people?", and is part of the WHO process for updating guidance (...) on the use of LF-LAM.To assess the accuracy of LF-LAM for the diagnosis of active tuberculosis among HIV-positive adults with signs and symptoms of tuberculosis (symptomatic participants) and among HIV-positive adults irrespective of signs and symptoms of tuberculosis (unselected participants not assessed for tuberculosis signs and symptoms).The proposed role for LF-LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis.We searched the Cochrane Infectious

2019 Cochrane